Stryker's Q1 Adjusted EBITDA Misses Consensus by 33%; JPMorgan Cuts Price Target
SYK is trading near its 52-week low of $294.55 (0.1% above the low) on elevated volume (2.1× avg).
Summary
Stryker reported Q1 2026 adjusted EBITDA of $1.06 billion, missing consensus estimates by a substantial 32.8%. This significant earnings miss for a large-cap company is a material negative surprise, likely to exert considerable downward pressure on the stock, particularly as it is already trading near its 52-week low. The company also announced a strategic reorganization, creating a new Ortho Tech segment by merging orthopaedic tools with its Mako robotic surgery platform, a move that is overshadowed by the financial underperformance. JPMorgan maintained its 'Overweight' rating but reduced its price target from $445 to $400 in response to the results. Traders will be closely watching for further details on the drivers of the miss and any updated guidance from management.
At the time of this announcement, SYK was trading at $294.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $112.9B. The 52-week trading range was $294.55 to $404.87. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.